Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Lupin Limited (LUPIN.NS)
Mumbai, IN
Lupin Limited is a pharmaceutical firm dedicated to the creation, manufacturing, commercialization, and distribution of a wide array of branded and generic medications, biotechnology items, and active pharmaceutical ingredients (APIs). Its comprehensive product portfolio addresses diverse therapeutic categories, including cardiovascular health, diabetes management, asthma, pediatric care, central nervous system disorders, gastrointestinal issues, anti-infectives, nonsteroidal anti-inflammatory drug (NSAID) therapy, respiratory ailments, women's health, and anti-tuberculosis treatments. Beyond its primary offerings, Lupin also supplies biosimilars and over-the-counter (OTC) medicines, alongside specialized pharmaceutical products. The company actively pursues drug discovery and development initiatives focused on oncology, immunology, and metabolic disorders, complementing these efforts with bio-clinical research. Lupin Limited maintains an extensive operational network comprising 18 laboratories, 280 LupiMitra collection centers, and 450 pick-up points. Its global presence extends across numerous countries, such as India, the United States, the United Kingdom, South Africa, Australia, the Philippines, Germany, the Netherlands, Mexico, and Brazil. Originally named Lupin Chemicals Limited, the company adopted its current identity, Lupin Limited, in 2001 following its merger with Lupin Laboratories Limited. Established in 1968, Lupin Limited is based in Mumbai, India.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.74% | -7.42% | -2.62% | +2.79% | +11.74% | +7.74% | +11.42% | +193.78% | +87.48% | +40.60% | +28,097.27% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 10 | 0 |
| Buy | 15 | -1 |
| Hold | 7 | -1 |
| Sell | 2 | 0 |
| Strong Sell | 2 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+23.1% ★ Q1'26: +31.9% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+62.4% ★ Q1'26: +89.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+20.0% ★ Q1'26: +31.2% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+24.7% ★ Q1'26: +24.2% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+27.0% ★ Q1'26: +27.7% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.1% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.81× ★ Q1'26: 0.76× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2010 actual |
Mar 2011 actual |
Mar 2012 actual |
Mar 2013 actual |
Mar 2014 actual |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 33 Rev. Ana. 32 EPS Ana. |
Mar 2027 31 Rev. Ana. 33 EPS Ana. |
Mar 2028 31 Rev. Ana. 32 EPS Ana. |
Mar 2029 25 Rev. Ana. 26 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
47.74B
est: 48.36B (-1.3%)
|
57.07B
est: 57.57B (-0.9%)
|
70.83B
est: 70.11B (+1.0%)
|
96.41B
est: 93.97B (+2.6%)
|
127.70B
est: 113.32B (+12.7%)
|
127.70B
est: 130.85B (-2.4%)
|
141.32B
est: 137.31B (+2.9%)
|
173.67B
est: 174.30B (-0.4%)
|
157.77B
est: 157.35B (+0.3%)
|
146.65B
est: 165.01B (-11.1%)
|
153.75B
est: 159.75B (-3.8%)
|
151.63B
est: 153.85B (-1.4%)
|
164.05B
est: 164.82B (-0.5%)
|
166.42B
est: 163.09B (+2.0%)
|
200.11B
est: 199.04B (+0.5%)
|
227.08B
est: 225.32B (+0.8%)
|
271.26B
259.51B – 280.61B
+20.4% YoY
|
287.75B
269.33B – 316.42B
+6.1% YoY
|
303.99B
282.75B – 346.46B
+5.6% YoY
|
345.18B
322.05B – 386.64B
+13.5% YoY
|
| EBITDA |
9.98B
est: 8.13B (+22.8%)
|
12.00B
est: 10.62B (+12.9%)
|
14.51B
est: 13.69B (+6.0%)
|
23.47B
est: 18.32B (+28.1%)
|
37.53B
est: 26.53B (+41.5%)
|
37.53B
est: 36.52B (+2.8%)
|
37.18B
est: 40.20B (-7.5%)
|
45.76B
est: 49.76B (-8.0%)
|
31.21B
est: 39.71B (-21.4%)
|
25.61B
est: 16.69B (+53.4%)
|
23.41B
est: 25.13B (-6.9%)
|
25.24B
est: 20.96B (+20.4%)
|
19.66B
est: 23.80B (-17.4%)
|
15.73B
est: 25.94B (-39.3%)
|
36.27B
est: 28.13B (+28.9%)
|
50.51B
est: 40.83B (+23.7%)
|
49.37B
47.23B – 51.07B
+20.9% YoY
|
52.37B
49.01B – 57.58B
+6.1% YoY
|
55.32B
51.46B – 63.05B
+5.6% YoY
|
62.82B
58.61B – 70.36B
+13.5% YoY
|
| EBIT |
8.74B
est: 8.97B (-2.6%)
|
10.29B
est: 10.52B (-2.2%)
|
12.24B
est: 12.53B (-2.3%)
|
20.19B
est: 16.85B (+19.8%)
|
33.28B
est: 23.87B (+39.4%)
|
33.28B
est: 32.89B (+1.2%)
|
32.43B
est: 34.13B (-5.0%)
|
36.79B
est: 41.25B (-10.8%)
|
20.50B
est: 32.31B (-36.5%)
|
17.15B
est: 6.28B (+173.2%)
|
13.71B
est: 13.37B (+2.5%)
|
17.54B
est: 6.60B (+165.8%)
|
12.58B
est: 7.50B (+67.8%)
|
8.52B
est: 8.17B (+4.4%)
|
27.76B
est: 8.86B (+213.4%)
|
41.59B
est: 31.25B (+33.1%)
|
37.78B
36.15B – 39.09B
+20.9% YoY
|
40.08B
37.51B – 44.07B
+6.1% YoY
|
42.34B
39.38B – 48.26B
+5.6% YoY
|
48.08B
44.86B – 53.86B
+13.5% YoY
|
| Net Income |
6.82B
est: 6.61B (+3.1%)
|
8.63B
est: 8.11B (+6.3%)
|
8.68B
est: 10.50B (-17.4%)
|
13.14B
est: 11.63B (+13.0%)
|
24.03B
est: 15.87B (+51.4%)
|
24.03B
est: 21.55B (+11.5%)
|
22.61B
est: 24.76B (-8.7%)
|
25.57B
est: 28.85B (-11.3%)
|
2.51B
est: 23.03B (-89.1%)
|
6.07B
est: 2.64B (+129.6%)
|
-2.69B
est: 5.87B (-145.9%)
|
12.17B
est: -2.70B (+550.9%)
|
-15.28B
est: -3.06B (-398.8%)
|
4.30B
est: -3.34B (+228.8%)
|
19.14B
est: -3.62B (+628.8%)
|
32.82B
est: 32.39B (+1.3%)
|
50.37B
41.98B – 55.67B
+55.5% YoY
|
45.24B
41.43B – 52.32B
-10.2% YoY
|
46.69B
39.44B – 53.39B
+3.2% YoY
|
62.53B
57.08B – 72.29B
+33.9% YoY
|
| SGA |
13.30B
est: 14.73B (-9.7%)
|
16.35B
est: 18.77B (-12.9%)
|
16.82B
est: 24.07B (-30.1%)
|
26.71B
est: 35.37B (-24.5%)
|
18.57B
est: 41.42B (-55.2%)
|
18.57B
est: 47.94B (-61.3%)
|
22.93B
est: 46.37B (-50.5%)
|
30.42B
est: 71.53B (-57.5%)
|
30.72B
est: 65.22B (-52.9%)
|
29.66B
est: 71.30B (-58.4%)
|
30.74B
est: 63.79B (-51.8%)
|
29.15B
est: 68.90B (-57.7%)
|
30.81B
est: 78.25B (-60.6%)
|
31.84B
est: 85.27B (-62.7%)
|
35.93B
est: 92.47B (-61.1%)
|
40.80B
est: 45.81B (-10.9%)
|
55.38B
52.98B – 57.29B
+20.9% YoY
|
58.75B
54.99B – 64.60B
+6.1% YoY
|
62.07B
57.73B – 70.74B
+5.6% YoY
|
70.48B
65.75B – 78.94B
+13.5% YoY
|
| EPS |
15.84
est: 14.99 (+5.7%)
|
19.36
est: 19.64 (-1.4%)
|
19.43
est: 22.25 (-12.7%)
|
29.39
est: 27.42 (+7.2%)
|
53.54
est: 40.01 (+33.8%)
|
53.54
est: 54.04 (-0.9%)
|
50.23
est: 50.36 (-0.3%)
|
56.69
est: 62.75 (-9.7%)
|
5.56
est: 31.21 (-82.2%)
|
11.32
est: 21.69 (-47.8%)
|
-8.82
est: 18.83 (-146.8%)
|
26.84
est: 23.94 (+12.1%)
|
-33.65
est: 26.91 (-225.0%)
|
9.46
est: 8.37 (+13.0%)
|
42.05
est: 42.77 (-1.7%)
|
71.95
est: 71.11 (+1.2%)
|
109.98
91.66 – 121.55
+54.7% YoY
|
98.77
90.46 – 114.23
-10.2% YoY
|
101.96
86.12 – 116.58
+3.2% YoY
|
136.53
124.63 – 157.84
+33.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Emerging Markets Ex-China ETF VEXC | 0.07% | 171.6K | 0.07% |
| 2 | Schwab Emerging Markets Equity ETF SCHE | 0.06% | 7.50M | 0.06% |
| 3 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L | 0.05% | 3.12M | 0.17% |
| 4 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Accumulating VFEA.L | 0.05% | 3.12M | 0.17% |
| 5 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.05% | 688.4K | 0.48% |
| 6 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.05% | 1.55M | 0.26% |
| 7 | Vanguard FTSE Emerging Markets ETF VWO | 0.05% | 76.63M | 0.06% |
| 8 | Vanguard FTSE Asia ex Japan Shares Index ETF VAE.AX | 0.04% | 266.4K | 0.40% |
| 9 | Vanguard ESG International Stock ETF VSGX | 0.02% | 1.14M | 0.10% |
| 10 | Vanguard All-World ex-US Shares Index ETF VEU.AX | 0.01% | 618.7K | 0.04% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Vinita D. Gupta | Chief Executive Officer & Executive Director | 271M | female |
| Nilesh Deshbandhu Gupta | MD & Executive Director | 111M | male |
| Ramesh Swaminathan | Executive Director, Global Chief Financial Officer, CRO & Head of API Plus SBU and IT | 83M | male |
| Rajalakshmi Azariah | Vice President & Global Head of Corporate Communications | — | female |
| Ravi Agrawal | Sr. Vice President of Investor Relations and M&A | — | male |
| Shahin Fesharaki | Chief Scientific Officer | — | — |
| Sofia Mumtaz | President of Legal and Compliance, Canada, ANZ, and NEA business | — | — |
| Amit Kumar Gupta | Company Secretary & Compliance Officer | — | male |
| Yashwant S. Mahadik | President of Global Human Resources | — | male |
| Christoph Funke | Chief Technical Operations Officer | — | male |
| Fabrice Egros | President of Corporate Development | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for LUPIN.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
